A wide variety of skin signs have been associated with internal malignancy. Cutaneous manifestations may develop before an internal neoplasm is recognized, and the skin findings can aid in diagnosis. In some cases the skin is infiltrated by malignant cells that represent metastatic or local spread from an internal malignancy. In other cases, the skin lesions are related to the underlying presence of malignancy, but they do not contain malignant cells. This issue of Dermatologic Clinics contains information on topics such as malignancy and cancer treatment-related hair and nail changes, tumor invasion of the skin, radiation therapy toxicity to the skin, and epidermal manifestations of internal malignancy.
Author(s): Valencia Thomas, Charles R. Thomas Jr. MD
Series: The Clinics: Dermatology
Publisher: Saunders
Year: 2007
Language: English
Commentary: 53788
Pages: 167
Cover......Page 1
Preface......Page 2
Acanthosis nigricans and tripe palms......Page 3
Acrokeratosis paraneoplastica......Page 5
The sign of Leser-TrElat......Page 6
Sweet’s syndrome......Page 7
Dermatomyositis......Page 8
Necrobiotic xanthogranuloma......Page 9
Scleromyxedema......Page 10
Hypertrophic osteoarthropathy......Page 11
Cushing’s syndrome......Page 12
Summary......Page 13
References......Page 14
Clinical manifestations......Page 18
Histopathology......Page 19
Clinical manifestations......Page 20
Clinical manifestations......Page 21
Treatment......Page 22
Clinical features and associated malignancies......Page 23
History......Page 24
Clinical manifestations......Page 25
History and epidemiology......Page 26
References......Page 27
Paraneoplastic calcium deposition of the dermis and subcutis......Page 31
Acute febrile neutrophilic dermatosis (Sweet syndrome)......Page 32
Erythema elevatum diutinum......Page 34
Scleromyxedema......Page 35
Scleredema......Page 36
Necrobiotic xanthogranuloma......Page 37
POEMS syndrome......Page 38
Cryoglobulinemias......Page 39
Erythema gyratum repens......Page 40
References......Page 41
Carcinoid syndrome......Page 44
Medullary carcinoma of the thyroid......Page 46
Primary telangiectasia......Page 47
Diseases related to vascular inflammation: vasculitis......Page 48
Thrombophlebitis and thromboembolism......Page 49
Cutaneous ischemia......Page 51
References......Page 52
Normal hair physiology......Page 57
Alopecia areata......Page 58
Anagen effluvium......Page 59
Normal nail physiology......Page 60
Acquired digital clubbing......Page 61
Nonspecific nail changes......Page 62
Nail plate abnormalities......Page 63
References......Page 64
Genodermatoses with Cutaneous Tumors and Internal Malignancies......Page 67
Extracutaneous tumors and features......Page 68
Cutaneous features......Page 69
Cutaneous features......Page 70
Extracutaneous tumors and features......Page 71
Molecular genetics (PTEN/MMAC1 gene on chromosome 10q23)......Page 72
Gardner syndrome......Page 73
Tuberous sclerosis......Page 74
Cutaneous features......Page 75
Cutaneous features......Page 76
Molecular genetics (NF1 gene on chromosome 17q11.2)......Page 77
Molecular genetics (NF2 gene on chromosome 22q12.2)......Page 78
Molecular genetics (FH gene at chromosome 1q42.3-43)......Page 79
References......Page 80
Mechanisms of metastasis......Page 86
Solid organ malignancies that metastasize to the skin......Page 87
En cuirasse metastatic carcinoma......Page 88
Breast carcinoma of the inframammary crease......Page 90
Colorectal carcinoma......Page 91
Carcinoma of the genitourinary systems......Page 92
Lymphoma cutis......Page 93
Clinical presentation......Page 94
Treatment......Page 95
Histology......Page 96
References......Page 97
Alopecia......Page 100
Acral erythema......Page 102
Epidermal dysmaturation......Page 103
Hyperpigmentation......Page 104
Chemotherapy and radiation recall and sensitivity reactions......Page 106
Irritants......Page 107
Vesicants......Page 108
Hypersensitivity......Page 109
Targeted therapy......Page 111
Summary......Page 112
References......Page 113
Introduction......Page 117
The ‘‘novel’’ epidermal growth factor receptor inhibitor-induced rash......Page 119
Dose-to-rash strategy......Page 122
Issues with assessing rash......Page 123
Management of rash-active......Page 131
Other epidermal growth factor receptor inhibitor cutaneous adverse events......Page 136
Non-epidermal growth factor receptor multikinase inhibitors......Page 138
Sorafenib (Bay 439006)......Page 139
Novel multikinase inhibitor toxicity: subungual splinter hemorrhages......Page 142
Imatinib......Page 143
Proteosome inhibitors......Page 144
Immunomodulatory drugs......Page 145
References......Page 148
Histology of the skin......Page 156
Radiation biology......Page 157
Response of the skin to radiation therapy......Page 159
Process improvements in radiation therapy support improved patient outcome......Page 160
Drug-radiography interactions......Page 162
Secondary cutaneous malignancies as a consequence of cancer management......Page 163
Skin care for the radiation therapy patient......Page 164
References......Page 165
